Scalper1 News
Capping what has been a big year for biotech IPOs, Bellicum Pharmaceuticals (BLCM) bolted on its public debut Thursday, with Juno Therapeutics coming next. Bellicum raised $140 million by offering 7.35 million shares at 19, above its 15-17 range. Shares were trading near 26.20, up 40%, midday in the stock market today. Houston-based Bellicum is developing cellular immunotherapy for the treatment of cancer. It’s a clinical stage biopharmaceutical Scalper1 News
Scalper1 News